Patents by Inventor Mark Smyth

Mark Smyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted isoquinolinones
    Publication number: 20050113399
    Abstract: Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
    Type: Application
    Filed: September 29, 2004
    Publication date: May 26, 2005
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Robert Scarborough, Kim Kane-MaGuire, Charles Marlowe, Mark Smyth, Xiaoming Zhang
  • Method and apparatus for automatically generating a phase lock loop (PLL)
    Publication number: 20040177334
    Abstract: A method that automatically generates a design for an analog phase lock loop (PLL) core in response to a desired clock frequency.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 9, 2004
    Inventors: John Horan, John Ryan, Ciaran Cahill, Stephen Dunphy, Mark Smyth, Kay Hearne, Niall Donovan, Tholom Kiely
  • Method and apparatus for automatically generating a phase lock loop (PLL)
    Patent number: 6704908
    Abstract: A method that automatically generates a design for an analog phase lock loop (PLL) core in response to a desired clock frequency.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: March 9, 2004
    Assignee: Amadala Limited
    Inventors: John Horan, John Ryan, Ciaran Cahill, Steven Dunphy, Mark Smyth, Kay Hearne, Niall O'Donovan, Tholom Kiely
  • Integrin antagonists
    Patent number: 6552079
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20030055244
    Abstract: Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis
    Type: Application
    Filed: April 26, 2002
    Publication date: March 20, 2003
    Inventors: Robert M. Scarborough, Mukund Mehrotra, Anjali Pandey, Mark Smyth
  • Integrin antagonists
    Publication number: 20010034369
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Application
    Filed: May 15, 2001
    Publication date: October 25, 2001
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Integrin antagonists
    Patent number: 6245809
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: June 12, 2001
    Assignees: Cor Therapeutics Inc., Eli Lilly & Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Melphalan derivatives
    Patent number: 5075108
    Abstract: A compound of formula I ##STR1## wherein R.sub.1 is of formula II ##STR2## wherein R.sub.4 and R.sub.5, which may be the same or different, are bromo, chloro, iodo or alkylsulphonyl;R.sub.2 is of formula III ##STR3## wherein R.sub.6 and R.sub.7, which may be the same or different, are H, alkyl, aryl, carboxy, hydroxy or amino and n is 0-10; andR.sub.3 is hydroxy or a group capable of being cleared and replaced by a radical having an antigen binding site or R.sub.3 is a radical having an antigen binding site.
    Type: Grant
    Filed: December 21, 1987
    Date of Patent: December 24, 1991
    Assignee: Consolidated Pharmaceuticals, Limited
    Inventors: Ian F. C. McKenzie, Geoffrey A. Pietersz, Mark Smyth